ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape. Read More
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
ResMed has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.9%. The stock now trades at $281.96, marking a 20.7% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025.
Medical device company ResMed (NYSE:RMD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts’ consensus estimates.
ResMed (RMD) offers a strong dividend with steady growth, backed by solid profitability and financial health, making it ideal for long-term income investors.
Shares of medical device company ResMed (NYSE:RMD)
jumped 3.1% in the afternoon session after the company reported strong fourth-quarter financial results that surpassed analyst estimates.
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts’ consensus estimates.
ResMed trades at $254.11 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 5.4%.
